{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:26:04Z","timestamp":1783689964791,"version":"3.55.0"},"reference-count":70,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T00:00:00Z","timestamp":1353024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Heart rate (HR) is a precisely regulated variable, which plays a critical role in health and disease. Elevated resting HR is a significant predictor of all-cause and cardiovascular mortality in the general population and patients with cardiovascular disease (CVD). \u03b2-blocking drugs exert negative effects on regional myocardial blood flow and function when HR reduction is eliminated by atrial pacing; calcium channel antagonists (CCAs) functionally antagonize coronary vasoconstriction mediated through \u03b1-adreno-receptors and are thus devoid of this undesired effect, but the compounds are nevertheless negative inotropes. From these observations derives the necessity to find alternative, more selective drugs to reduce HR through inhibition of specific electrical current (If). Ivabradine (IVA) is a novel specific HR-lowering agent that acts in sinus atrial node (SAN) cells by selectively inhibiting the pacemaker If current in a dose-dependent manner by slowing the diastolic depolarization slope of SAN cells, and by reducing HR at rest during exercise in humans. Coronary artery diseases (CAD) represent the most common cause of death in middle\u2013aged and older adults in European Countries. Most ischemic episodes are triggered by an increase in HR, that induces an imbalance between myocardial oxygen delivery and consumption. IVA, a selective and specific inhibitor of the If current which reduced HR without adverse hemodynamic effects, has clearly and unequivocally demonstrated its efficacy in the treatment of chronic stable angina pectoris (CSAP) and myocardial ischemia with optimal tolerability profile due to selective interaction with If channels. The aim of this review is to point out the usefulness of IVA in the treatment of ischemic heart disease.<\/jats:p>","DOI":"10.3390\/molecules171113592","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T11:03:15Z","timestamp":1353063795000},"page":"13592-13604","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ivabradine: An Intelligent Drug for the Treatment of Ischemic Heart Disease"],"prefix":"10.3390","volume":"17","author":[{"given":"Graziano","family":"Riccioni","sequence":"first","affiliation":[{"name":"Intensive Cardiology Care Unit, San Camillo de Lellis Hospital, Manfredonia, via Isonzo, 71043 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,11,16]]},"reference":[{"key":"ref_1","unstructured":"Morrow, D.A., Gersh, B.E., and Braunwald, E. (2005). Braunwald\u2019s Heart Disease, Elsevier Saunders. [7th]."},{"key":"ref_2","unstructured":"O\u2019Rourke, R.A., O\u2019Gara, P., and Douglas, J.S. (2004). Hurst\u2019s The Heart, McGraw Hill Medical Publishing Division. [11th]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/VHRM.S7564","article-title":"Recent advances in the management of chronic stable angina I: Approach to the patients, diagnosis, pathophysiology, risk stratification and gender disparities","volume":"6","author":"Kones","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1517\/14656566.2011.634799","article-title":"Treatment strategies for chronic stable angina","volume":"12","author":"Kaski","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1540-8167.2006.00736.x","article-title":"The pacemaker current: From basics to the clinics","volume":"18","author":"Barbuti","year":"2007","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrd3576","article-title":"Exploring HCNchannels as novel drug targets","volume":"10","author":"Postea","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1050-1738(02)00162-7","article-title":"Cardiac HCN channels: Structure, function, and modulation","volume":"12","author":"Biel","year":"2002","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2011.01507.x","article-title":"HCN channelopathies: Pathophysiology in genetic epilepsy and therapeutic implications","volume":"165","author":"Reid","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","article-title":"The role of the funny current in pacemaker activity","volume":"106","author":"DiFrancesco","year":"2010","journal-title":"Circ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.hrthm.2009.10.030","article-title":"Funny channel-based pacemaking","volume":"7","author":"DiFrancesco","year":"2010","journal-title":"Heart Rhythm"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.yjmcc.2009.06.019","article-title":"The cardiac pacemaker current","volume":"48","author":"Baruscotti","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-200767002-00003","article-title":"The funny current: Cellular basis for the control of heart rate","volume":"67","author":"DiFrancesco","year":"2007","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bjp.0706940","article-title":"Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity","volume":"150","author":"Thollon","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00424-010-0810-8","article-title":"HCN-related channelopathies","volume":"460","author":"Baruscotti","year":"2010","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1152\/physrev.00029.2008","article-title":"Hyperpolarization-activated cation channels: From genes to function","volume":"89","author":"Biel","year":"2009","journal-title":"Physiol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00018-008-8525-0","article-title":"HCN channels: Structure, cellular regulation and physiological function","volume":"66","author":"Biel","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3390\/molecules17044225","article-title":"HCN channels and heart rate","volume":"17","author":"Scicchitano","year":"2012","journal-title":"Molecules"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00581906","article-title":"Acetylcholine inhibits activation of the cardiac hyperpolarizing-activated current If","volume":"410","author":"DiFrancesco","year":"1998","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1113\/jphysiol.1988.sp017344","article-title":"Muscarinic control of the hyperpolarization-activated current (If) in rabbit sino-atrial node myocytes","volume":"405","author":"DiFrancesco","year":"1988","journal-title":"J. Physiol."},{"key":"ref_20","unstructured":"Summary of Product Characteristics. Procoralan\u2122 (ivabradine hydrochloride). Available online:http:\/\/emc.medicines.org.uk."},{"key":"ref_21","unstructured":"European Public Assessment Report (EPAR): Scientific discussion for Procoralan. Available online:http:\/\/www.emea.eu.int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0022-3565(25)12114-9","article-title":"Coronary and haemodynamic effects of S16257, a new bradycardic agents, in resting and exercising conscious dogs","volume":"275","author":"Simon","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","article-title":"Pharmacokinetic\u2014pharmacodynamic modelling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers","volume":"64","author":"Ragueneau","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/jphysiol.1991.sp018457","article-title":"The contribution of pacemaker current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes","volume":"34","author":"DiFrancesco","year":"1991","journal-title":"J. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1520-765X(03)90004-6","article-title":"If inhibition: A novel mechanism of action","volume":"5","author":"DiFrancesco","year":"2003","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/280235a0","article-title":"How does adrenaline accelerate the heart?","volume":"280","author":"Brown","year":"1979","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(90)90011-T","article-title":"Use and frequency-dependent blockade by UL-FS 49 of the I(f) pacemaker current in sheep cardiac Purkinie fibres","volume":"187","author":"VanBogaert","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/eurheartj\/8.suppl_L.91","article-title":"Clinical pharmacology of two specific bradycardiac agents","volume":"8","author":"Franke","year":"1987","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00507111","article-title":"N-allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site","volume":"306","author":"Kobinger","year":"1979","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1476-5381.1993.tb13815.x","article-title":"Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells","volume":"110","author":"BoSmith","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","article-title":"If inhibition with ivabradine: Electrophysiological effects and safety","volume":"31","author":"Savelieva","year":"2008","journal-title":"Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00392-010-0220-0","article-title":"Ivabradine for the treatment of stable angina pectoris in octogenarians","volume":"100","author":"Koester","year":"2011","journal-title":"Clin. Res. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/14656566.2011.548321","article-title":"Ivabradine: Recent and potential applications in clinical practice","volume":"12","author":"Riccioni","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000095430","article-title":"Novel If current inhibitor ivabradine: Safety considerations","volume":"43","author":"Savalieva","year":"2006","journal-title":"Adv.Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1586\/14779072.7.2.107","article-title":"Focus on ivabradine","volume":"7","author":"Riccioni","year":"2009","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.bjp.0706998","article-title":"Cellular mechanisms underlying the pharmacological induction of phosphenes","volume":"150","author":"Cervetto","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1749-6632.2011.05960.x","article-title":"Innovation in coronary artery disease and heart failure: Clinical benefits of pure heart rate reduction with ivabradine","volume":"1222","author":"Canet","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2010.10.065","article-title":"BEAUTIFUL Investigators. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)","volume":"107","author":"Tendera","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijcard.2010.10.035","article-title":"Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography","volume":"156","author":"Guaricci","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.hrthm.2010.05.034","article-title":"Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia","volume":"7","author":"Rebecchi","year":"2010","journal-title":"Heart Rhythm"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2009.08.642","article-title":"Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus","volume":"105","author":"Borer","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.transproceed.2010.05.125","article-title":"Safety and effectiveness of ivabradine after cardiac transplantation","volume":"42","author":"Machuca","year":"2010","journal-title":"Transplant. Proc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00126839-200304020-00001","article-title":"Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology","volume":"4","author":"Camm","year":"2003","journal-title":"Drugs R. D."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2010.05.038","article-title":"Heart rate correction of the QT duration in rats","volume":"641","author":"Kmecova","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1152\/ajpheart.00591.2008","article-title":"Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure","volume":"296","author":"Milliez","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_48","unstructured":"Summary of Product Characteristics (last update 16 February 2012). Available online:http:\/\/www.medicines.org.uk\/EMC\/medicine\/17188\/SPC\/Procoralan\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/0091270006291623","article-title":"Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: An open-label, pharmacokinetic interaction clinical trial","volume":"46","author":"Terleira","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2710.2010.01170.x","article-title":"Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers","volume":"36","author":"Vlase","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jclinepi.2005.11.002","article-title":"Can we improve cardiovascular risk prediction beyond risk equations in the physician\u2019s office?","volume":"59","author":"Aboyans","year":"2006","journal-title":"J. Clin. Epidemiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factors in patients with coronary artery diasease and left-ventricular systolic dysfuunction (BEAUTIFUL): A subgoup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000073933","article-title":"A single dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction","volume":"100","author":"Manz","year":"2003","journal-title":"Cardiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","article-title":"Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure","volume":"10","author":"Mazzuero","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/0091270006291624","article-title":"Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: An open-label, randomized, crossover, pharmacokinetic interaction clinical trial","volume":"46","author":"Calvo","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1358\/dot.2008.44.3.1193864","article-title":"Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases","volume":"44","author":"Tardif","year":"2008","journal-title":"Drugs Today"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blockers therapy: A 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10557-011-6327-3","article-title":"Efficacy of ivabradine in combination with beta-blocker versus up titration of beta-blocker in patients with stable angina","volume":"25","author":"Amosova","year":"2011","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","article-title":"Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: Results from the ADDITIONS study","volume":"101","author":"Werdan","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Riccioni, G., Prencipe, G.A., Benvenuto, A., Masciocco, L., Ventra, S., Rizzo, U., Russi, C., and Speziale, G. (2012). Ivabradine Improves All Aspects of Quality of Life Assessed with the 36-Item Short Form Health Survey in Subjects with Chronic Ischemic Heart Disease Compared with Beta-Blockers. Pharmacology.","DOI":"10.1159\/000343631"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cardfail.2009.05.013","article-title":"Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: Preliminary findings","volume":"15","author":"Fasullo","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00059-009-3231-8","article-title":"Ivabradine\u2014A new therapeutic option for cardiogenic shock?","volume":"34","author":"Post","year":"2009","journal-title":"Herz"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00392-011-0323-2","article-title":"Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I(f) (funny channel current) inhibitor ivabradine. MODI(f)Y trial","volume":"100","author":"Nuding","year":"2011","journal-title":"Clin. Res. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bjp.2008.347","article-title":"Pleiotropic action(s) of the bradycardic agent ivabradine: Cardiovascular protection beyond heart rate reduction","volume":"155","author":"Heusch","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehn337","article-title":"Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: Protection beyond heart rate reduction","volume":"29","author":"Heusch","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12325-010-0014-9","article-title":"Ivabradine: from molecular basis to clinical effectiveness","volume":"27","author":"Riccioni","year":"2010","journal-title":"Adv. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/molecules17054924","article-title":"The biological effects of ivabradine in cardiovascular disease","volume":"17","author":"Speranza","year":"2012","journal-title":"Molecules"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/17\/11\/13592\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:53:38Z","timestamp":1760219618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/17\/11\/13592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,16]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"alternative-id":["molecules171113592"],"URL":"https:\/\/doi.org\/10.3390\/molecules171113592","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,16]]}}}